Testing a new drug for advanced prostate cancer
Treatments studied
This study tests a new drug for prostate cancer that has spread and is PSMA-positive. It aims to see if the drug is safe and effective for people who have already tried hormone therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have prostate cancer that has spread to other parts of the body.
- Your cancer must show PSMA on a PET scan.
- You must have already tried at least two types of hormone therapy.
- You cannot have had radiation therapy in the last 3 weeks.
- You cannot have brain metastases or certain other serious conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase study tests whether REGN4336 is safe and how well it works, by itself or with REGN5678, in adults with advanced prostate cancer. It may help people whose cancer has continued to worsen despite standard prostate cancer medicines.
This trial tests a new radioactive treatment, [225Ac]Ac-FL-020, for men with metastatic castration-resistant prostate cancer (mCRPC) that has gotten worse despite other treatments. It's for those who have had at least one prior hormone therapy or chemotherapy.
This trial tests a new drug combination that uses a radioactive molecule to find and treat prostate cancer cells that have spread and are no longer responding to hormone therapy. It may be an option for men with a specific protein called PSMA on their cancer cells.
This trial tests a new radioactive drug, 225Ac-PSMA-Trillium, that targets prostate cancer cells. It is for people whose advanced prostate cancer has stopped responding to hormone therapy and may have spread.
This Phase 1 study tests a new drug that aims to attach to PSMA on prostate cancer cells and activate T-cells (an immune cell type) to attack the cancer. It is for men with advanced prostate cancer that no longer responds to hormone therapy, especially after several prior treatments.
This trial tests a new drug called INR731, given by mouth, for men with prostate cancer that has spread to other parts of the body. The study will check if the drug is safe and how well it works, either alone or combined with other prostate cancer medicines.
Hear when a new PSMA-positive Metastatic Castration-resistant Prostate Cancer (mCRPC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.